| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H21NOS2 |
| Molecular Weight | 355.517 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](NCC=C(C1=CSC=C1)C2=CSC=C2)[C@H](O)C3=CC=CC=C3
InChI
InChIKey=JQSHEDRVRBSFCZ-YWZLYKJASA-N
InChI=1S/C20H21NOS2/c1-15(20(22)16-5-3-2-4-6-16)21-10-7-19(17-8-11-23-13-17)18-9-12-24-14-18/h2-9,11-15,20-22H,10H2,1H3/t15-,20-/m0/s1
| Molecular Formula | C20H21NOS2 |
| Molecular Weight | 355.517 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Tinofedrine is a dithienylamine derivative patented by Deutsche Gold- und Silber-Scheideanstalt vorm. Roessler for improvement of cerebral and peripheral blood flow. In anesthetized dogs, Tinofedrine causes a remarkable increase of cardiac output by positive inotropic and chronotropic stimulation of the heart and simultaneous reduction of peripheral vascular resistance. In comparison with typical beta-agonists Tinofedrine at isotropically equieffective doses, has a much weaker effect on the heart rate. In coronary circulation, Tinofedrine causes vasodilation so that in a therapeutic dose range increased workload is equalized by sufficient myocardial supply.
Approval Year
PubMed
Patents
|
|
SALT/SOLVATE -> PARENT |
Showing 1 to 1 of 1 entries
